Vaccination to help prevent shingles now is available for adults aged 50 to 59 years as well as for those aged 60 years and older. The US Food and Drug Administration (FDA) announced its approval of the expanded age range for the vaccine, marketed as Zostavax, in late March.
“The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease,” Karen Midthun, MD, director of the FDA's Center for Biologics Evaluation and Research, said in a statement.
Voelker R. FDA Expands Age Range for Shingles Vaccine. JAMA. 2011;305(15):1526. doi:10.1001/jama.2011.495
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: